Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Dual inhibition of angiopoietin-TIE2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma. 31582532 2020
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Cabozantinib is a potent inhibitor of VEGF, AXL and MET receptors providing rationale for its use in RCC. 31184937 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Other tyrosine kinases' pathways, including PDGFR, Axl or MET have emerged as key signaling pathways involved in RCC biology. 30999623 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Combination strategies of VEGF and MET inhibitors could lead to sustained and deep responses even in non-MET driven RCC by inhibiting pathways of VEGF resistance. 31554440 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation disease BEFREE Likewise, papillary RCC has also been studied at the molecular level, which has shown a high level of mutations in the MET gene; early clinical data suggest the utility of MET targeted therapy. 30478013 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE The significance of ligand-dependent MET activation in RCC bone metastasis is considered, and HAI-2 may be an important regulator in this system. 29890660 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation disease BEFREE Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology. 30017898 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE MET inhibitors are actively being developed for papillary RCC with a specific focus on MET-driven tumors. 30372389 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation disease BEFREE Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor receptor as a promising target for RCC therapeutic agents.We have examined MET expression, frequency of MET gene copy gains and MET gene mutation in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.Out of a total of 572 clear-cell RCC, only 17% were negative for MET expression whereas 32% showed high protein levels. 27894094 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE C-Met protein levels were increased in 8 of 10 RCC tissue samples compared with their adjacent normal tissue and c-Met expression levels were positively associated with a high nuclear grade (P = 0.008) and pT stage (P = 0.002). 28427859 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE We report here two pediatric patients with recurrent metastatic RCC whose tumors expressed MET and were treated with cabozantinib. 28417541 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Interfering RNA-induced stable inhibition of <i>NRF2</i> in ovarian carcinoma SKOV3 and renal carcinoma A498 reduced the levels of c-MET and EGFR. 29291022 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE In the present study, tissue microarrays containing sunitinib-treated and untreated RCC tissues were stained with MET and AXL antibodies. 26364599 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Renal cell carcinoma (RCC) is a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing (VHL/HIF pathway alterations and the subsequent up-regulation of HIF-responsive genes such as VEGF, PDGF, EGF, and glucose transporters GLUT1 and GLUT4, which justify the RCC reliance on aerobic glycolysis), energy sensing (fumarate hydratase-deficient, succinate dehydrogenase-deficient RCC, mutations of HGF/MET pathway resulting in the metabolic Warburg shift marked by RCC increased dependence on aerobic glycolysis and the pentose phosphate shunt, augmented lipogenesis, and reduced AMPK and Krebs cycle activity) and/or nutrient sensing cascade (deregulation of AMPK-TSC1/2-mTOR and PI3K-Akt-mTOR pathways). 27453294 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient. 26951228 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease CTD_human Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. 25401301 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis. 25186085 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation disease BEFREE Dysregulation of c-Met and hepatocyte growth factor have been observed in both clear cell and non-clear cell renal cell carcinomas (RCCs), although only papillary RCCs harbor activating mutations in the MET gene. 23867513 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma. 24767687 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. 24658158 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma. 23219378 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Investigation of rare familial forms of renal cell carcinoma (RCC) has led to the identification of genes such as VHL and MET that are also implicated in the pathogenesis of sporadic RCC. 24000165 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation disease BEFREE Common genetic aberrations in renal cell carcinomas (RCCs) include loss of function of the VHL gene in clear-cell RCC, overexpression of the c-MET gene in papillary RCC type I, deficiency in the FH gene in papillary RCC type II and loss of heterozygozity of the BHD gene in chromophobe RCC. 23895657 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation disease BEFREE Germline mutations in the MET and fumarate hydratase (FH) genes lead to the development of type 1 and type 2 papillary RCCs, respectively, and such mutations of either the TSC1 or TSC2 gene increase the risk of RCC. 21228928 2010
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation disease BEFREE MET is the gene for the hereditary form of type 1 papillary renal carcinoma and is mutated in a subset of sporadic type 1 papillary kidney cancers. 20059341 2010